Psychedelic Business Spotlight – December 10
This week in psychedelic business news: Wesana Health files a new patent, Silo Pharma is granted a patent, and 2 companies explore a merger.
Author: Emily Jarvie
Non-Hallucinogenic DMT? Psilera Bioscience Reports Progress on ‘Well-Tolerated’ Derivative
Further in vivo studies with PSIL-002 will evaluate its antidepressant, anxiolytic, and anti-addictive properties, specifically targeting alcohol consumption.
You Can Make ‘Bad Trips’ Good with Storytelling, Psychedelics Study Shows
Evidence supports the idea that the possibly unpleasant nature of the psychedelic experience is an integral part of its therapeutic benefits.
Toronto Moves to Decriminalize Psychedelics
Proposed legislation decriminalizes personal possession and use of all illegal drugs in an effort to focus on health and social equity instead of criminalization.
Microdosing LSD and Psilocybin Rises During Pandemic, Global Drug Survey Finds
The report also explores how microdosing may impact the use of other prescribed mental health medications.
Psychedelic Business Spotlight: December 3
This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
DEA Boosts Psychedelics Production (Again) to Meet Research Demand
Drug Enforcement Agency also addresses concerns from Native American Church regarding peyote poaching for mescaline research.
Celebrities: Are They Helping or Harming the Psychedelic Movement?
Two industry insiders weigh in on the question as more and more of the world’s biggest stars publicly share psychedelic experiences.
Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy Trial
Chief Medical Officer Dr. Guy Goodwin clarifies “COMP360 psilocybin therapy was generally well-tolerated” by patients with treatment-resistant depression, despite some adverse reactions from subjects in the study.
New Study Suggests SSRI Drugs Can Be Used Safely with Psilocybin to Treat Depression
“If the results are confirmed in subsequent studies … antidepressants may no longer need to be stopped for psilocybin treatment,” says MindMed Executive President Dr. Miri Halperin Wernli.
End of content
End of content